Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
- 29 February 2012
- journal article
- practice guideline
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (4), 734-738
- https://doi.org/10.1038/clpt.2011.355
Abstract
Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.Keywords
This publication has 39 references indexed in Scilit:
- Delayed drug hypersensitivity: models of T‐cell stimulationBritish Journal of Clinical Pharmacology, 2011
- Pharmacogenetics of drug hypersensitivityPharmacogenomics, 2010
- Host Determinants of HIV‐1 Control in African AmericansThe Journal of Infectious Diseases, 2010
- Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 TherapyNew England Journal of Medicine, 2009
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNature Genetics, 2009
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationThe Lancet, 2008
- Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utilityThe Pharmacogenomics Journal, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1Science, 2007
- National marrow donor program HLA-matching guidelines for unrelated marrow transplantsTransplantation and Cellular Therapy, 2003